Infiltration of Alternatively Activated Macrophages in Cancer Tissue Is Associated with MDSC and Th2 Polarization in Patients with Esophageal Cancer

Jingjing Gao1,3,*, Yumin Wu1†, Zhaoliang Su1, Prince Amoah Barnie1, Zhijun Jiao2, Qingli Bie1, Liwei Lu4, Shengjun Wang1,4, Huaxi Xu1‡

1 Department of Immunology, School of Medical Science and Laboratory Medicine, Jiangsu University, Zhenjiang, P. R. China, 2 Department of Laboratory Medicine, Affiliated Hospital of Jiangsu University, Zhenjiang, P. R. China, 3 Department of Laboratory Medicine, Suzhou Hospital Affiliated to Nanjing Medical University, Suzhou, P. R. China, 4 Department of Pathology and Centre of Infection and Immunology, The University of Hong Kong, Hong Kong, P. R. China

Abstract

Myeloid derived suppressor cells (MDSCs) expand in cancer bearing hosts and contribute to tumor immune evasion. M2 macrophages constitute a major cellular component of cancer-related inflammation. However, the correlation between circulating MDSCs and infiltrating M2 macrophages in tumor tissues from patients with esophageal cancer (ECA), and its potential relationship with the polarization of Th2 cells remain unclear. In the present study, we showed the level of MDSCs in PBMC and Arg1 in plasma were significantly elevated in ECA patients, and the increased ratio of MDSC in PBMC was closely related to the expression of CD163 in cancer tissues. In addition, the ECA patients exhibited remarkable increases in the mRNA levels of IL-4 and GATA3, as well as the protein levels of IL-13 and IL-6, but IFN-γ and IL-12 in peripheral blood were decreased. Our data indicate that the increased Th2 cytokines are associated with MDSCs and M2 macrophages polarization, and foster the infiltration of CD163+M2 macrophages in cancer tissues, which promote the formation of immunosuppressive microenvironment in ECA patients.

Citation: Gao J, Wu Y, Su Z, Amoah Barnie P, Jiao Z, et al. (2014) Infiltration of Alternatively Activated Macrophages in Cancer Tissue Is Associated with MDSC and Th2 Polarization in Patients with Esophageal Cancer. PLoS ONE 9(8): e104453. doi:10.1371/journal.pone.0104453

Editor: Jacques Zimmer, Centre de Recherche Public de la Santé (CRP-Santé), Luxembourg

Received March 4, 2014; Accepted July 9, 2014; Published August 21, 2014

Copyright: © 2014 Gao et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by grants from the National Natural Science Foundation of China (31270947, 31170849 and 30972748, http://www.nsfc.gov.cn/), Natural Science Foundation of Jiangsu Province (BK2011472) and the Postdoctoral Foundation of China (2012MS11705). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* Email: xuhx@ujs.edu.cn (HX); sjwjs@ujs.edu.cn (SW)

† These authors are co-first authors on this work.

Introduction

Esophageal cancer (ECA) is one of the most common malignancies all over the world and the fourth leading cancer death in China [1–3]. There are increasing evidences of the crucial role of the immune system in malignant tumors, but the precise mechanisms of immune modulation in ECA patients remain elusive. In the past decade, the role of the immunosuppressive and cancer-promoting myelomonocytic compartment within the tumor environment has also received a great deal of attention [4]. Although mechanisms are incompletely understood, cancer promotes the accumulation of a heterogeneous pool of bone marrow-derived immature, poorly differentiated myelomonocytic cells (monocytes, neutrophils, immature macrophages and dendritic cells), called myeloid derived suppressor cells (MDSCs), which are major host component contributing to the immuno-suppressive environment. In pathological conditions, a partial block in the differentiation of immature myeloid cells into matured myeloid cells results in an expansion of MDSCs [5]. Recently, it has become clear that the suppressive activity of MDSCs requires various factors which promote their expansion or induce their activation. These factors, which include IL-4, IL-13, ligands for Toll-like receptors (TLRs), and transforming growth factor-β (TGF-β), activate several different signalling pathways in MDSCs that involve STAT6 and nuclear factor-kB (NF-kB).

Similar to MDSCs, macrophages are a diverse population of myeloid cells which undergo specific differentiation depending on the stimulating agents, as documented extensively. Recent immunological studies have identified two distinct states of the polarized macrophage activation: the classically activated (or M1) and the alternatively activated (or M2) macrophage phenotypes. M1 macrophages are typically activated by IFN-γ and LPS, whereas M2 macrophages are activated by IL-4 and IL-13 [6]. M1 macrophages are tumoricidal and promote tumor rejection, whereas M2 macrophages promote tumor progression [7–9]. Both M2 macrophages and MDSCs are a major source of immunosuppression that allows tumor-escape from effective anti-cancer responses, but no information on the relationship between M2 macrophages and MDSCs in the development of esophageal cancer is currently available.

An exciting observation has been described in the laboratory of Dr Teramoto, whose group show that simultaneous activation of Th1 function can augment the potency of dendritic cell-based cancer immunotherapy [10]. In our previous study, we have found that there is a predominant Th2 phenotype in patients with gastric cancer [11]. It is conjectured that the imbalance of Th1/Th2 may
Contribute to the occurrence and development of tumor. MDSCs and/or M2 macrophages, as major host components contributing to the suppressive environment of tumor immunity [12], their polarization should be related to the immune balance disorders. In the current study, we analyzed the levels of M2 macrophages and MDSCs in ECA patients, detected the expression of some related factors including Th1/Th2 type cytokines and evaluated the relationship between Th2 cells and M2 macrophages or MDSCs. The general goal of the study was to contribute to better understanding of the significance of MDSCs and M2 macrophages from patients with esophageal cancer in Th2 cell polarization state.

Materials and Methods

Patients
Fifty newly diagnosed ECA patients receiving treatment at the Affiliated People’s Hospital of Jiangsu University were included in this study: 38 males and 12 females, with mean age 61.97 ± 1.24 years. None of the patients had undergone radiotherapy or chemotherapy prior to the start of the current study. The characteristics of ECA patients were summarized in Table 1. All primary tumor cases were staged clinically according to the guidelines of the International Union for Cancer Control and American Joint Committee on Cancer (UICC-AJCC) updated the tumor-node-metastasis (TNM) cancer staging system [13]. Thirty healthy volunteers without any chronic inflammatory condition were studied simultaneously as control, comprising 24 males and 6 females. Enrollment took place between March 2011 and December 2012. This study was approved by the ethical committee of Jiangsu University, and written informed consent was obtained from all individuals.

Cell preparation
Peripheral blood samples were collected from ECA patients and healthy volunteers. Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-Hypaque density-gradient centrifugation (GE Healthcare). The cell suspensions were divided into two equal aliquots; one was immediately used for the experiments. The other was cryopreserved at −80°C and thawed for testing at a later date.

Flow cytometry
MDSCs population was defined as HLA-DR−/CD14+/CD11b+CD33+. Heparinized venous blood was freshly obtained from ECA patients or healthy volunteers. PBMCs were isolated by standard Ficoll-Hypaque density centrifugation, and stained with the following antibody mix: FITC-conjugated anti-human HLA-DR, PerCP-Cy5.5-conjugated anti-human CD14, APC-conjugated anti-human CD11b, or PE-conjugated anti-human CD33. The isotype control antibody was used in all cases. Data acquisition and analysis were performed on a FACSCalibur flow cytometer (Becton Dickinson, CA, USA) using CellQuest software (Becton Dickinson, CA, USA).

Table 1. Characteristics of ECA patients enrolled for the study.

| Characteristics | Early disease* (n = 11) | Advanced disease* (n = 39) |
|-----------------|------------------------|--------------------------|
| Age             |                        |                          |
| >60             | 9                      | 34                       |
| ≤60             | 2                      | 5                        |
| Sex             |                        |                          |
| Male            | 8                      | 30                       |
| Female          | 3                      | 9                        |
| Location        |                        |                          |
| Upper           | 2                      | 7                        |
| Middle          | 6                      | 24                       |
| Lower           | 3                      | 8                        |
| Tumor size      |                        |                          |
| >3 cm           | 3                      | 30                       |
| ≤3 cm           | 8                      | 9                        |
| Histological grading |                |                          |
| Well-G1         | 4                      | 6                        |
| Moderate-G2     | 5                      | 28                       |
| Poor-G3         | 2                      | 5                        |
| TNM stageb      |                        |                          |
| I               | 11                     |                          |
| IIA             |                        |                          |
| IIB             |                        |                          |
| III             |                        |                          |
| IV              |                        |                          |

*aEsophageal cancer with early disease corresponds to stage I and those with advanced disease correspond to stages II, III, and IV.

bStage: according to the TNM classification for esophageal cancer (UICC, 2010). doi:10.1371/journal.pone.0104453.t001
RNA extraction and quantitative real-time PCR

Following the manufacturer’s instructions, total RNA was extracted from PBMCs using Trizol reagent (Invitrogen, Carlsbad, CA). Complementary DNA was synthesized from 1 μg total RNA using RT reagent kit (TaKaRa, Ohtsu, Japan). For quantitative real-time PCR, reverse transcribed cDNA (2 μl) was amplified by real-time PCR with the SYBR Green Premix EX Taq kit (TaKaRa, Ohtsu, Japan). Each sample was analyzed in duplicate with the CFX-96 Cycler (Thermal) and the normalized signal level was calculated based on its ratio to the corresponding β-actin.

### Table 2. Primers used in real-time PCR.

| Gene     | Upper/Lower | Sequence (5’-3’) | Length (bp) |
|----------|-------------|------------------|-------------|
| β-actin  | U           | CACGAAACTACCTTCAACT | 265         |
|          | L           | CATACCTCTGGCTTGGATC |            |
| IFN-γ    | U           | TTGGTTTCTCTGGCTGTAT | 96          |
|          | L           | ATCCCGTACATCTGAATGACCT |           |
| T-bet    | U           | CGGGAGAACCTTTGAGTCC | 115         |
|          | L           | ACTGGTGTGAGGAGGAGG |            |
| IL-4     | U           | GACATCTTGTGCGCTC  | 99          |
|          | L           | TACTCTGTTGCCCTTCTCA |           |
| GATA3    | U           | AGACCACCAACACCACACT | 122        |
|          | L           | GATGCGCTCCTCTCCATAGTCA |         |
| IL-12    | U           | TTGCTAATTCCAGAGAGA | 150         |
|          | L           | AGCCTTCATGCTGCTGCTG |            |
| IL-13    | U           | ATCCCTCCTGTGGGCAC  | 155         |
|          | L           | CTGGTTCTGGTGATGTTGAC |           |

IFN, Interferon; IL, Interleukin; U, Upper; L, Lower.
doi:10.1371/journal.pone.0104453.t002

### Table 3. Relationship between % MDSCs and clinical pathological profile.

|                        | n  | MDSC%   | P         |
|------------------------|----|---------|-----------|
| Age                    |    |         |           |
| > 60                   | 43 | 2.43±0.33 | >0.05    |
| ≤ 60                   | 7  | 1.78±0.27 |           |
| Sex                    |    |         |           |
| male                   | 38 | 2.38±0.29 | >0.05    |
| female                 | 12 | 1.52±0.22 |           |
| Tumor size(cm)         |    |         |           |
| > 3                    | 33 | 2.36±0.32 | >0.05    |
| ≤ 3                    | 17 | 1.88±0.28 |           |
| Histological grading   |    |         |           |
| Well- G1               | 10 | 0.77±0.16 | >0.05    |
| Moderate- G2           | 33 | 1.96±0.12 |           |
| Poor- G3               | 7  | 4.43±0.28 |           |
| Tumor infiltrating depth|    |         |           |
| T1+T2                  | 15 | 1.92±0.22 | >0.05    |
| T3+T4                  | 35 | 2.16±0.16 |           |
| Lymph node metastasis  |    |         |           |
| Yes                    | 17 | 3.71±0.34 | <0.0001  |
| No                     | 33 | 1.47±0.13 |           |
| TNM stage              |    |         |           |
| (Early cancer)         | 11 | 0.77±0.15 | <0.05    |
| II+III+IV (Advanced cancer) | 39 | 2.56±0.25 |           |

doi:10.1371/journal.pone.0104453.t003
housekeeping signal. Primers used in PCR were showed in Table 2.

Enzyme-linked immunosorbent assay (ELISA)
For quantitative detection of IFN-γ, IL-4, IL-6, IL-13 and Arg1 in plasma, commercially available ELISA kits were used according to the manufacturer’s instruction (Biovender). All samples were run in batches to minimize inter-assay variability and quantitated using a standard curve.

Immunohistochemistry
ECA tissues and paired adjacent tissues were fixed in 10% buffered formalin solution and embedded in paraffin. Serial sections of 4 μm were cut from the paraffin blocks. CD68 or CD163 antibody was used respectively to identify macrophages and M2 macrophage subtype. As negative controls, the primary antibodies were replaced by an irrelevant isotype anti-mouse IgG1. Immunohistochemical detection was performed using the avidin-biotin-peroxidase method. A multiheaded microscope was used to read immunohistochemical results, the detected cells were countered at 10 randomly selected areas by three different researchers at ×40 magnification. The final result was estimated according to the cell color depth and the percentage of stained cells.

Statistical analysis
The statistical analysis was performed with GraphPad Prism, Version 5.0, software (San Diego, CA, USA). Correlations between variables were determined by Spearman’s correlation coefficient. Comparisons between groups were performed using the Student’s unpaired or paired t test. Differences were considered statistically significant when the P-value <0.05.

Results
Elevated MDSCs correlated with increased plasma level of Arg1 in ECA patients
MDSCs, defined as HLA-DR⁻/CD14⁻/CD11b⁺/CD33⁺ cells, were determined by flow cytometry and calculated as % PBMC. The level of individual MDSCs was significantly elevated in ECA patients compared to healthy controls (P<0.05; Figure 1). As shown in Table 3, the proportion of MDSCs in patients with advanced cancer was significantly higher than that in patients with early cancer (2.56±0.25% vs. 0.77±0.15%; P<0.05). Moreover, the proportion of MDSCs in patients with lymph node metastasis was higher than those without lymph node metastasis (3.71±0.34% vs. 1.47±0.13%; P<0.0001). However, there were no significant differences between the proportion of MDSCs and the patients’ age, gender, tumor location, tumor size, or tumor
Figure 2. Immunohistochemical analysis of CD68 and CD163 expression in esophageal cancer and adjacent tissues. Representative immunohistochemical pictures showed the expression of CD68 in a cancer-adjacent tissue (a), and a cancer tissue (b). Representative immunohistochemical pictures showed the expression of CD163 in a cancer-adjacent tissue (c), and a cancer tissue (d). Normal esophageal squamous epithelium (haematoxylin-eosin/HE staining) (e). Squamous cell esophageal carcinoma (HE staining) (f). Analysis of the number of CD68+ macrophages (g), and CD163+ macrophages (h), in cancer and cancer-adjacent tissues, the results showed that most cancer tissues had larger number of CD68+ and CD163+ macrophages infiltration than that in the cancer-adjacent tissues.

doi:10.1371/journal.pone.0104453.g002
Table 4. Expression of CD68/CD163 in esophageal cancer tissues and adjacent tissue.

| groups                  | n   | CD68/CD163* | positi | p     |
|-------------------------|-----|-------------|--------|-------|
| adjacent tissue         | 30  | 47/48       | 2/0    | 6     |
| cancer tissues          | 20  | 1/16        | 13/14  | 26/14 |

*Ten high magnification views were selected to count all cells, the cell color depth and the percentage of stained cells as the judgment result basis. According to the staining color (A): 0 = no color in cytoplasm; 1 = light yellow; 2 = pale brown; 3 = brown color. According to the percentage of stained cells (B): "0" indicates the percentage of positive cells <5%; "1" indicates the percentage of positive cells 5%-25%; "2" indicates the percentage of positive cells 26%-50%; "3" represents the percentage of positive cells >50%. The two scores of A plus B as a final judgment result: 0−: "−−"; 1−: "−+"; 1+: "++"; 2+: "+++"; 3+: "++++".

Table 5. Relation between CD163 expression in cancer tissues and MDSC% in PBMC from ECA patients.

| The number of patients | CD163 expression | MDSC% (x±s) | p     |
|------------------------|------------------|-------------|-------|
| 16                     | −                | 1.43±0.13   | <0.0001 |
| 14                     | +                | 2.23±0.05   |       |
| 20                     | ++               | 3.55±0.15   |       |

M2 Infiltration Relate to MDSC and Th2 Polarization in ECA

infiltrating depth. We also measured the plasma concentration of Arg1, which is one of the most important suppressive factors [14,15]. The result showed that control plasma had minimal Arg1 compared to ECA patients (9.57±1.51 ng/ml vs. 28.28±4.10 ng/ml; P<0.001). In addition, a positive correlation was found between the proportion of MDSCs from PBMC and plasma level of Arg1 in ECA patients in subsequent tests.

Enhanced M2 macrophages in ECA patients

CD163 is a scavenger receptor, upregulated by macrophages in anti-inflammatory environments [16] and regarded as a highly specific monocyte/macrophage marker for M2 macrophages [17–19]. Most papers in the meta-analysis used CD68 as a marker for tumor-associated macrophages (TAMs) [20]. CD68, however, recognizes both M1 and M2 macrophages [21]. Therefore, we used CD68 and CD163 as the markers of macrophages and M2 macrophages respectively. To analyze whether the localization of CD163+ and CD68+ macrophages had a correlation to clinical characteristics, the distribution of CD163+ and CD68+ macrophages in tumor and tumor-free tissues was evaluated separately (Figure 2). The staining categories were initially scored from 0 to 3 in macrophage infiltration density. Results showed that most tumor tissues had higher densities of CD163+ and CD68+ macrophages than those in the tumor-free tissues. The positive expression rates of CD163+ and CD68+ were 68% and 78% respectively in cancer tissues compared to 4% and 6% in the adjacent cancer tissues. Moreover, the increased ratio of MDSC in PBMC from ECA patients was closely related to the expression of CD163 in cancer tissues (Tables 4–5).

Increased IL-4 and GATA3 mRNA while decreased IFN-γ mRNA in PBMC from ECA patients

The relative expression levels of cytokine genes encoding IL-4, IL-6, IL-12, IL-13 and IFN-γ, as well as transcription factors GATA3 and T-bet were assessed using real-time PCR. As shown in Figure 3, ECA patients had increased expressions of IL-4 and GATA3 mRNA compared to the healthy controls (P<0.05); IFN-γ, IL-12, and IL-13 mRNA expressions in ECA group were significantly lower than those in the control group (all P<0.05). But no significant difference was found in terms of T-bet mRNA expression between the two groups (P>0.05).

Increased IL-6, IL-13, Arg1 in plasma from ECA patients

Plasma IFN-γ, IL-4, IL-6, IL-13, and Arg1 were determined by ELISA. As shown in Figure 4, IL-6 and IL-13 concentrations were significantly higher in the ECA patients compared to the control subjects (P<0.05 and P<0.001). In addition, a higher level of Arg1 was found in plasma from ECA patients. However, there were no significant differences in IFN-γ or IL-4 concentration between the two groups.

Correlation analysis between different cytokines in ECA patients

The correlations between the various cytokines in the ECA patients were analyzed. As shown in Figure 5, there was a significant positive correlation between the levels of Arg1 (MDSCs and M2 associated cytokine) and IL-13 (Th2 type cytokine) in plasma from the ECA patients. IL-4, as a cytokine of Th2, the mRNA expression was increased following the plasma Arg1 enhancement, but a negative correlation was found between IFN-γ and Arg1. In addition, the concentration of IL-13 in plasma showed positive correlation with the mRNA level of IL-4 in PBMC (r = 0.43, P<0.05).

Discussion

MDSCs, under normal conditions migrate to different peripheral organs and differentiate into dendritic cells, macrophages and/or granulocytes. However, factors produced in the tumor microenvironment, alone or in combination, promote the accumulation of MDSCs, prevent their differentiation and induce their activation. In the tumor environment, MDSCs can also differentiate into TAMs, which are a unique phenotype whose function is distinct from MDSCs [5]. Macrophages are plastic cells, as they can switch from an activated M1 state back to an M2/TAMs state, and vice versa, upon the induction of specific signals. Macrophages infiltrating in cancer tissues are referred to as

Table 5. Relation between CD163 expression in cancer tissues and MDSC% in PBMC from ECA patients.
TAMs, which are closely involved in the development of the tumor microenvironment. Heterogeneity of phenotypes is observed among TAMs in various malignant tumors, and a significant proportion of TAMs/M2 phenotype is associated with a worse clinical prognosis and high grade of malignancy [22]. In 2007, Sinha et al. [23], used the spontaneously metastatic 4T1 mouse mammary carcinoma, and demonstrated that MDSCs impaired tumor immunity by suppressing T cell activation as well as interacting with macrophages to increase IL-10 and decrease IL-12 production, thereby promoting a tumor-promoting type 2 response, a process which can be partially reversed by gemcitabine. Based on this, our study targeted ECA and investigated MDSCs in peripheral blood, macrophages in the tumor tissues and the levels of some related factors. As expected, increased MDSCs were found in peripheral blood, and some amount of M2 macrophages infiltrated into the tumor sites, which indicated that these cell populations were involved in the pathogenesis of ECA. In addition, increased plasma level of Arg1, which was correlated with MDSCs and M2 macrophages functions, was also found in ECA patients. Notably, the increased ratio of MDSCs in PBMCs from ECA patients was closely related to the expression of CD163 in cancer tissues.

Previously we showed that there was a predominant Th2 phenotype in gastric cancer patients, and it was believed that the
Th2 associated cytokines IL-4, IL-13, IL-6 and transcriptional factors GATA3 might closely be related to the polarization of M2 and MDSCs, and fostered an immunosuppressive environment in cancer patients. In the present study, we demonstrated that ECA patients exhibited remarkable increases in the mRNA levels of IL-4 and GATA3, as well as the plasma levels of IL-13 and IL-6. In contrast, plasma level of IFN-γ and mRNA levels of IFN-γ and IL-12 were decreased. There was a positive correlation between the mRNA level of IL-4 and plasma level of IL-13, and these two cytokines increased following the Arg1 enhancement in plasma. In the meantime, a negative correlation was found between IFN-γ and Arg1. The present data indicated that there was a predominant Th2 phenotype in ECA patients and it was consistent with increased level of Arg1, which was MDSCs and M2 associated cytokine. Recently, Gabitass et al. [24], reported that MDSCs were elevated in pancreatic and gastric cancer, and demonstrated they were an independent prognostic factors and associated with significant elevation of the Th2 cytokine IL-13. These results were partly consistent with our data. It should be mentioned that the IL-4 mRNA was increased in PBMC, while expression of IL-4 protein in plasma was unchanged in cancer patients. It was not an entirely consistent result, which might due to IL-4 gene transcription and its protein secretion were not synchronous, further research was necessary to investigate this in more detail.

Some researchers believe that IL-4 and IL-13 are enough to play important roles in M2 macrophages activation [6]. In addition, Gabitass RF et al. [24] and Pesc JT et al. [25], indicated that the Th2 cytokines: IL-4 and IL-13 can upregulate arginase activity thereby increasing the suppressive function of MDSCs and M2 macrophages. Therefore, we propose that IL-4, IL-13 and Arg1 are key factors mediating the distribution of MDSCs and M2 macrophages, and are closely related to Th2 cell polarization. Ostrand-Rosenberg et al. [26], show that cross-talk between MDSCs and macrophage promotes synergy among these cells thereby augments the immune suppressive effects of the individual cell populations. As a result, MDSCs and macrophages in the tumor microenvironment are inextricably interconnected so that the functions of one population are impacted by the quantity of the other populations [27–30]. In a recent review of survival analyses, it was found that many studies have indicated clinical and pathologic characteristics of patients with esophageal carcinoma as explanatory variables with respect to survival, and showed a better survival rate for women or young patients. The reasons for this are likely to include a combination of better general health and more effective immune state [31–32]. However, there were limitations with the present study in which the correlation between MDSCs% and the clinical pathological factors of ECA patients were not analyzed, it should be considered in our future work.

**Conclusion**

We revealed an interesting connection between Th2 cells associated cytokines and MDSCs or M2 macrophages in ECA. The changes detected in the IL-4, IL-6, IL-13 and GATA3 levels correlated positively with MDSCs and M2 macrophages activation, but IFN-γ played the opposite effect. The close relationship between circulating MDSCs and tissue infiltration of M2 macrophages indicated that infiltration of M2 macrophages in ECA tissues might be related to MDSCs polarization involving Th2 advantage. These results provide better understanding of systemic immunosuppression such as the interaction between T cells and MDSCs or M2 macrophages, systemic cytokines and their signalling pathways, and may contribute to triggering new strategies for anticancer therapy, which are based on modulation of the immunosuppressive effects of tumor-associated MDSCs, M2 macrophages and Th2 cells.
Acknowledgments

The authors are grateful to Zhijian Zhang, Sheng Xia, Qixiang Shao and Peifang Yang for excellent technical help. This work was supported by grants from the National Natural Science Foundation of China (31170849 and 30972748), Natural Science Foundation of Jiangsu Province (BK2011472) and Postdoctoral Foundation of China (2012M511705).

References

1. Crew KD, Neugut AI (2004) Epidemiology of upper gastrointestinal malignancies. Semin Oncol 31: 450–464.
2. Arantes V, Fereira Pires EA, Yoshimura K, Tsyrua A (2012) Advances in the management of early esophageal carcinoma. Rev Col Bras Cir 39: 534–543.
3. Go M, Li SY, Huang XE, Lin Y, Cheng HY, et al. (2012) A phase II study on continuous infusional paclitaxel and 5-Fu as first-line chemotherapy for patients with advanced esophageal cancer. Asian Pac J Cancer Prev 13: 5587–5591.
4. Nagaraj S, Gahalawar DI (2010) Myeloid-derived suppressor cells in human cancer. Cancer J 16: 348–353.
5. Gahalawar DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9: 162–174.
6. Gordon S (2003) Alternative activation of macrophages. Nat Rev Immunol 3: 23–35.
7. Mantovani A, Sica A, Locati M, Allavena P, Sica A. (2002) Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23: 549–555.
8. Mantovani A, Sica A, Locati M (2005) Macrophage polarization comes of age. Immunity 23: 344–346.
9. Guiducci C, Vicari AP, Sangari S, Trinchieri G, Colombi MP (2005) Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res 65: 3437–3446.
10. Terramoto K, Ohshio Y, Fujita T, Hanaoka J, Kontani K (2013) Simultaneous activation of Th1 helper function can augment the potency of dendritic cell-based cancer immunotherapy. Cancer Res Clin Oncol 139: 861–870.
11. Xu Y, Gao J, Su Z, Dai X, Li Y (2012) Downregulation of Hlx closely related to the decreased expressions of T-bet and Runx3 in patients with gastric cancer may be associated with a pathological event leading to the imbalance of Th1/Th2. Clin Dev Immunol 2012: 949821.
12. Sinha P, Clements VK, Ostrand-Rosenberg S (2005) Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol 174: 636–645.
13. Sobin LH, Compton CC (2010) TNM seventh edition: what’s new, what’s changed: communication from the International Union Against Cancer and the American Joint Committee on Cancer: Cancer 116: 5336–5339.
14. Bronze T, Zanovello P (2005) Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol 5: 641–654.
15. Rodriguez PC, Ochoa AC (2008) Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev 222: 180–191.
16. Buechler C, Ritter M, Oros E, Langmann T, Knackert J, et al. (2000) Regulation of scavenger receptor CD163 expression in human monocyes and macrophages by pro- and antiinflammatory stimuli. J Leukoc Biol 67: 97–103.
17. Ambursus CA, Krause S, van Eijk M, Hamann J, Rackstate TR, et al. (2012) Systematic validation of specific phenotypic markers for in vitro polarized human macrophages. J Immunol Methods 375: 196–206.
18. Lau SK, Chu FG, Weiss LM (2004) CD163: a specific marker of macrophages in paraffin-embedded tissue samples. Am J Clin Pathol 122: 794–801.
19. Nguyen TT, Schwartz EJ, West RR, Warnke RA, Arber DA, et al. (2005) Expression of CD163 (hemoglobin scavenger receptor) in normal tissues, lymphomas, carcinomas, and sarcomas is largely restricted to the monocyte/macrophage lineage. Am J Surg Pathol 29: 617–624.
20. Bingle L, Brown NJ, Lewis CE (2002) The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 196: 254–265.
21. Holness CL, Simmons DL (1993) Molecular cloning of CD68, a human macrophage marker related to lysosomal glycoproteins. Blood 81: 1607–1613.
22. Fujitaya Y, Takeya M, Komohara Y (2014) A Novel Strategy for Inducing the Antitumor Effects of Triterpenoid Compounds: Blocking the Pronomulatory Functions of Tumor-Associated Macrophages via STAT3 Inhibition. Biomed Res Int 2014: 348539.
23. Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S (2007) Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol 178: 977–985.
24. Gabitaux RF, Amels NE, Stocken DID, Pandha HA, Middleton GW (2011) Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immu: 1419–1429.
25. Pecce JT, Ramalingam TR, Mentink-Kane MM, Wilson MS, El Kasi MC (2009) Arginase-1-expressing macrophages suppress Th2 cytokine-driven inflammation and fibrosis. PLoS Pathog 5: e1000371.
26. Ostrand-Rosenberg S, Sinha P, Beary DW, Clements VK (2012) Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin Cancer Biol 22: 275–281.
27. Ma J, Wang S, Ma B, Mao C, Tong J, et al. (2011) Dendritic cells engineered to express GITRL enhance therapeutic immunity in murine Lewis lung carcinoma. Cancer Lett 301: 142–150.
28. Ghosh AK, Basu S (2012) Tumor macrophages as a target for Capsaicin mediated immunotherapy. Cancer Lett 324: 91–97.
29. Zhang QW, Liu L, Gong CY, Shi HS, Zeng YH, et al. (2012) Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS One 7: e50946.
30. Cui YL, Li HK, Zhou HY, Zhang T, Li Q (2013) Correlations of Tumor-Associated Macrophage Subtypes with Liver Metastases of Colorectal Cancer. Asian Pac J Cancer Prev 14: 3281.
31. Hajian-Tilaki KO (2001) Factors affecting the survival of patients with advanced esophageal cancer: implications for new anticancer therapies. Asian Pac J Cancer Prev 14: 1003–1007.
32. Delpech A, Veisani Y, Sayehmiri K, Rahimi E (2014) Esophageal carcinoma: long-term survival in consecutive series of patients through a retrospective cohort study. Gastroenterol Hepatol Bed Bench 7(2): 101–107.

Author Contributions

Conceived and designed the experiments: JG LL SW HX. Performed the experiments: JG YW PAB ZJ QB. Wrote the paper: JG SW HX. Read and approved the final manuscript: JG YW ZS PAB ZJ LL SW HX.